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ABSTRACT 
 
The vaginal microbiota (VMB) is a complex and delicate balance between different bacterial 
species and is normally dominated by Lactobacillus species. Under the effect of hormonal 
changes, behavioral or sexual activity VMB could lose this balance resulting in diseases. 
Bacterial vaginosis (BV) is one of the most common vaginitis affecting women and is defined 
as an increase in proportion of anaerobic bacteria and a reduction or absence of lactobacilli. BV 
has been linked with increased risk of acquiring sexually transmitted diseases (STDs) including 
infection by human immunodeficiency virus type-1 (HIV-1). Vulvovaginal candidiasis (VVC) 
is the second most common cause of vaginitis after BV, which is recognized by an overgrowth 
of yeast mainly belonging to the genus Candida and albicans species. The standard clinical 
treatment for these conditions prescribes antibiotics (clindamycin and/or metronidazole) and 
antifungal (fluconazole). This thesis focuses on investigating clinical interventions for the 
treatment of BV and VVC and attempting to express neutralizing antibody fragments in 
Lactobacillus against HIV-1 for future applications. 
 
An extended antibiotic treatment with clindamycin and metronidazole together with adjuvant 
lactobacilli was tested in order to achieve long lasting cure and reduce relapse of BV (paper I). 
Five different combinations of Lactobacillus strains were tested which included newly 
characterized strains (paper I) and the commercial EcoVag
®  
capsules (a mixture of L.gasseri 
DSM 14869 and L. rhamnosus DSM 14870). The cure rate was 74.6% after six months and 
65.1% after 12 months. No significant difference was observed in cure rates depending on 
whether the women were colonized by any of the given strains. However, change of sexual 
partner was significantly associated with relapse of BV. The results were further confirmed in 
another clinical trial (paper II, trial I). 
 
We subsequently assessed the efficacy of a prolonged treatment with EcoVag
® 
lactobacilli in 
combination with similar antibiotic treatment in BV patients (paper II, trial II). The cure rate 
was 66.7% and 62.5% after six months and 12 months respectively and was comparable to that 
in paper I. Prolonged treatment with lactobacilli did not significantly improve the colonization 
by EcoVag
® 
strains. Overall colonization by any lactobacilli and by EcoVag strains was 
associated with cure of BV. Once again change of sexual partner was associated with relapse of 
BV. We also tested for the first time, a combination of EcoVag
® 
and anti-fungal for treatment 
of recurrent VVC and evaluated if lactobacilli can colonize women when the microbiota is not 
disturbed by antibiotics. All the women were cured of VVC after six months and 87.5% 
remained cured after 12 months. EcoVag
® 
strains colonized more in the presence of prior 
antibiotic treatment in BV patients and in women with VVC who were not colonized by 
lactobacilli in the beginning of the study. 
 
The VMB has been extensively studied in European and American populations albeit less so in 
the African population. Therefore we have identified the vaginal Lactobacillus species in a 
group of 40 women in South Africa (paper III). We found that the vaginal Lactobacillus species 
identified were similar to those in other populations, suggesting that the strategies utilising 
probiotic and engineered lactobacilli could be applied in Africa. Finally llama-derived single 
domain antibody fragment (VHH) against HIV-1 glycoprotein gp140 was expressed in L. 
paracasei BL23 (our model strain) (paper IV). The VHH was expressed in secreted and cell 
surface anchored form, which were able to bind to recombinant HIV-1 glycoproteins. The VHH 
is currently being tested for in vitro neutralization of various HIV-1 viral strains. These results 
provide the basis for the use of lactobacilli and genetically modified lactobacilli for treatment of 
BV, yeast infection and HIV-1 in both developed and developing world. 
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1    INTRODUCTION 
 
1.1    Vaginal microbiota (VMB) 
 
The human body is long known to coexist with microbial communities specific to 
different  mucosal  sites  such  as  gastrointestinal  tract,  oral  cavity  and  vagina.  The 
number of bacteria that closely exist with humans outnumber human cells by a factor of 
10 (1). A bacillus for the first time was isolated from vagina a century ago in 1892 by 
Doderlein and was named after him which was later renamed as Lactobacillus (2). 
VMB is a complex balance of different bacterial species present in the vagina. In a 
healthy woman, VMB is dominated by Lactobacillus species and the most commonly 
identified species are L. crispatus, L. jensenii, L. gasseri, L. iners followed by L. 
rhamnosus,  L.  reuteri,  L.  vaginalis,  L.  acidophilus,  L.  casei,  L.  fermentum,  L. 
plantarum and L. salivarius (3–7). Other than the lactobacilli, Prevotella, 
Peptostreptococcus and Porphyromonas are the species also normally present in the 
vagina but in very low numbers (8). In some of the studies, Gardnerella vaginalis has 
also been reported to be present in women with Lactobacillus dominated microbiota 
(9,10). More than 50 vaginal microbial species have been identified (11–13) which 
coexist with each other. Studies on vaginal microbiota of different populations have 
resulted in a mixed opinion on dominant colonizing lactobacilli in women from 
different ethnicity. Some studies performed with white, black, Hispanic and Asian 
women have suggested that the composition of VMB vary between these ethnic groups 
and was not dominated by lactobacilli in black women (14,15). However, the studies 
from Nigeria and South Africa suggest that the colonizing lactobacilli in these cohorts 
are similar to those identified in European and American populations (5,6). An internal 
factor that affects the composition of VMB is menstrual cycle. During the menstrual 
cycle, the proportion of colonizing lactobacilli increases as the cycle progress post 
menses whereas species like Prevotella and Bacteroides increase significantly before 
menses (16). A Lactobacillus dominated microbiota confers protection against sexually 
transmitted diseases (STDs) including infection by HIV-1, Neisseria gonorrhoeae, 
herpes simplex virus-2 (HSV-2) and human papillomavirus by preventing pathogenic 
organisms from surviving and infecting the host cell (17–21). 
 
 
1.2    Lactobacillus 
 
Lactobacillus is a genus of Gram-positive facultative anaerobic or microaerophilic rod- 
shaped bacteria. Lactobacillus, along with Lactococcus, Streptococcus, Leuconostoc, 
Enterococcus to name a few, is the member of lactic acid bacteria (LAB) group. These 
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are recognized to produce lactic acid as a fermentation product and maintain a lower 
pH (< 4.5) which is protective against pathogenic microbes (22). Lactobacillus is a 
major part of the vaginal and gastrointestinal microbiota. In the vagina, Lactobacillus 
provide a protective environment by maintaining a low pH, by producing bacteriocin 
and through competitive exclusion (23–26). During the perinatal period and from 
puberty to menopause, high estrogen levels stimulate the deposition of glycogen on the 
vaginal epithelium. This glycogen is metabolized anaerobically by lactobacilli to 
produce acetic and lactic acid and lowers the vaginal pH (27). Among the identified 
vaginal  colonizers  from  the  Lactobacillus  genus  L.  crispatus  has  been  shown  to 
stabilize the VMB and is less affected by the changes during the menstrual cycle 
(28,29), whereas L. iners is suggested to be a dominant part of the VMB when the 
microbiota is in a transitional stage between abnormal and normal (28,30). 
 
 
The  presence  of  lactobacilli  in  general  and  their  impact  on  microenvironment 
contribute to the homeostasis of VMB. Many of the Lactobacillus species including L. 
acidophilus and L. salivarius were tested for production and activity of bacteriocin 
against BV associated bacteria (31–33) and were found to inhibit their growth. H2O2 
and its effect have been studied by several groups and have resulted in contradictory 
results. Many of the studies did establish an inverse association between the presence of 
H2O2 producing bacteria and BV and have also shown an inhibitory effect of H2O2 
against pathogens like Neisseria gonorrhoeae, HIV and diverse anaerobes 
(19,23,25,34,35). However, in contrast, a study by O’Hanlon et al. showed that H2O2 
present in the vaginal fluid could not suppress the growth of BV associated bacteria 
(36). Factors such as adherence to epithelial cells, colonization resistance and other 
antimicrobial agents also contribute to the vaginal colonization and subsequent health 
status. 
 
 
1.3    Imbalance of the vaginal microbiota 
 
The vaginal microbiota represents a delicate balance between beneficial lactobacilli and 
other anaerobes, Mycoplasma and G. vaginalis, which in a normal microbiota are 
below detectable levels.  This delicate balance is affected by several participating 
factors like hormonal levels, vaginal practices, sexual practices, bacterial interactions, 
host defense and very recently studied dietary indices (37–39) which could lead to 
dramatic changes in VMB and clinical conditions like BV and VVC. 
3  
1.3.1    Bacterial vaginosis (BV) 
Menge  and  Kronig  at  the  end  of  19
th   
century  first  described  the  isolation  of  an 
anaerobic organism in addition to Lactobacillus from vagina (40). Using culture based 
techniques, Curtis in 1923, associated “white-discharge” syndrome with black- 
pigmented anaerobes, curved anaerobic motile rods, anaerobic cocci and Gram-variable 
rods (41). He also noted depletion of vaginal Lactobacillus in women with this 
syndrome. It was thus known that the symptomatic “vaginal discharge syndrome” was 
associated with significant changes in VMB. Later on, a Gram-variable coccobacillus 
was identified to be associated with the white discharge syndrome and named as 
Gardenerella vaginalis by Gardiner and Dukes in 1955 (41). For a long time this 
syndrome was associated only with G. vaginalis until 1980, when Spiegel et al. 
established an association between non-specific vaginitis and dramatic variations in 
VMB (42–44). Thereafter this syndrome was named as bacterial vaginosis. Further on 
the markers for diagnosing BV were identified by Amsel et al. as: 1- vaginal discharge 
with a pH level above 4.5; 2- malodourous discharge on addition of 10% potassium 
hydroxide (KOH); 3- presence of at least 20% of epithelial cells coated with bacteria 
named as “clue cells” and 4- a typically white thin homogenous vaginal discharge (45). 
Nugent et al. in 1991 standardized a method to interpret gram stained vaginal smears to 
diagnose BV (46), which since then has been widely accepted in clinics for the 
diagnosis of BV and classifying the VMB. In brief, a score of zero to four is given for 
the decreasing number of lactobacilli, a score of zero to four for increasing number of 
Gardnerella/Bacteroides  morphotypes  and  a  score  of  zero  to  two  is  given  for 
increasing number of curved Gram variable rods. The sum of all these scores is a 
representative of the status of VMB as normal (0-3), intermediate (4-6) and BV (7-10). 
In addition to Nugent scoring, Hay/Ison also defined a way of grading the vaginal 
smears with two additional categories. According to Hay/Ison scoring a vaginal smear 
is given grade I (normal) with presence of only lactobacilli morphotypes, grade II 
(intermediate) with reduced lactobacilli and other morphotypes, grade III (BV) with 
mixed morphotypes and few or no lactobacilli, grade 0 with epithelial cells with no 
bacteria seen and grade IV with only Gram positive cocci (47,48). BV is defined as an 
increase in proportion of BV associated bacteria like G. vaginalis, Bacteroides 
(Prevotella), Mycoplasma hominis, Mobiluncus species, Atopobium vaginae and 
reduction or absence of lactobacilli (49,50). The prevalence of BV is highest in sub- 
Saharan Africa (6.4-58.3%) whereas, it is comparatively less prevalent in other regions 
(Fig. 1) (51). 
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1.3.2    Vulvovaginal candidiasis (VVC) 
 
After BV, VVC is the most common vaginitis affecting women. VVC is caused by 
overgrowth of yeast belonging to the genus Candida and Candida albicans is one of 
the most common causative species and is a commensal of skin, gastrointestinal and 
reproductive tracts. Non-albicans species which have recently been associated with 
VVC are Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida 
krusei (52,53). Seventy to 75% of women experience VVC at least once in their life 
time  (54,55),  where  40  to  50%  of  women  suffer  from  1  or  more  episodes  after 
treatment for first episode (56). Candida species that have been associated with 
recurrence are non-albicans species (57) and C. glabrata is the most common species 
(58). Symptoms of VVC include thick vaginal discharge with a pH less than 4.5 and the 
presence of alkali resistant blastospores or hyphae of C. albicans in vaginal smears. 
Unlike in BV, lactobacilli are not depleted in VVC and coexist with Candida. A similar 
observation was made in paper II presented in this thesis. 
 
 
1.3.3    Risks associated with disturbed vaginal microbiota 
 
The disturbance in VMB with loss of lactobacilli increases the risk of acquiring vaginal 
infections including infection by HIV-1, Neisseria gonorrhoeae and favors the growth 
of G. vaginalis. BV associated bacteria have been shown to induce HIV-1 replication 
and shedding in the genital tract (59,60), which may increase infectivity of HIV-1 for 
5  
women with BV (61). H2O2 producing lactobacilli have been shown in vitro to inhibit 
G. vaginalis, other anaerobes, N. gonorrhoeae and HIV-1 (19,23,25,35,62). Other 
exhibited properties of lactobacilli which may protect the vaginal ecosystem include 
competition for attaching to epithelial cells and stimulation of the local immune system 
(11,63). Women harbouring H2O2  producing lactobacilli have been shown to be less 
likely than women without these lactobacilli to have BV as well as STD pathogens 
such as N. gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis 
(34,62,64). Moreover, abnormal VMB is shown to be associated with HSV-2 and HPV 
infections (20,21). BV associated VMB is also considered to be a risk factor for 
premature delivery, a leading cause of prenatal mortality (65,66). 
 
 
Hence, a VMB with no or a lower proportion of lactobacilli creates a permissive 
environment with a higher vaginal pH, lack of H2O2, bacteriocins and no competition 
with pathogens for binding to epithelial cells providing an opportunity for BV 
associated bacteria to colonize and STD pathogens to cause infection. In addition, BV- 
associated bacteria produce proteases like sialidases and prolidases, adversely affect 
vaginal mucosal cell exfoliation and degradation of mucus, glycoproteins, which are 
thought to be major components of the first line of defense against infection (67). 
 
 
1.4    Treatment of vaginal infections 
 
The current treatment strategies for vaginal infections include use of antibiotics, 
antifungal drugs alone and in combination with probiotic lactobacilli. In order to 
improve the cure rate and reduce recurrence rate, investigators are currently assessing 
the possible combination of antibacterial and antifungal drug together with probiotics. 
 
 
1.4.1    Current treatment regimens for BV and VVC 
 
According to the current treatment regimen women with BV are given clindamycin 
and/or metronidazole in the form of vaginal cream or administered orally (68). 
Treatment of BV prescribes either 2% clindamycin vaginal cream daily (5 grams (g)) 
for 7 days or 0.75% metronidazole vaginal cream (5 g) daily for 7 days or 500 
milligrams (mg) of oral metronidazole twice daily for 7 days. However, resistance for 
clindamycin in anaerobic bacteria has been observed after the treatment (69). Side 
effects for metronidazole has also been registered including nausea, metallic taste, 
transient neutropenia and gastrointestinal side effects (especially when administered 
orally) to name a few (70). 
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In the case of VVC, the current treatment strategy prescribes single dose of 150 mg 
fluconazole which has been shown to be inhibiting 90% of Candida species (71). 
Previously used oral ketoconazole which was effective in treating recurrent infection, 
use of vaginal boric acid or flucytosine to control C. glabrata are associated with severe 
side effects or are not safe for long term use (72–74). Hence, fluconazole is favoured 
over other antifungal drugs. 
 
 
1.4.2    Combination therapy with lactobacilli 
 
Use of lactobacilli with probiotic effect as a combination treatment with antimicrobial 
drugs has been suggested and investigated widely because of failure of antimicrobials 
to prevent recurrences. Treatment with antibiotics hamper the colonization of native 
vaginal microbial species post treatment mainly lactobacilli and in several cases leads 
to recolonization by pathogenic microbes, thereby increasing the recurrence rate 
(75,76).  The properties that are considered ideal for probiotic lactobacilli include 
adherence to vaginal epithelial cells, co-aggregation, exclusion of pathogen adhesion 
and production of bacteriocin. The route of administration of lactobacilli is also 
important. In most of the studies conducted till date, lactobacilli have been delivered 
intra-vaginally. Specific strains of lactobacilli have been tested for vaginal colonization 
and treatment of yeast infection or BV, when administered intra-vaginally or orally 
(77–80). The Lactobacillus strains tested, including L. rhamnosus GR-1, L. reuteri RC- 
14, L. crispatus CTV-05, L. gasseri DSM 14869, L. rhamnosus DSM 14870, L. 
fermentum LF10 and L. acidophilus LA02, were shown to improve the cure rate of BV 
and VVC (77,79,81–84). However, more studies are needed to establish the observed 
effect in general population. 
 
 
In paper I and II presented in this thesis, we were able to improve the long term cure 
rates for BV and VVC using EcoVag
® 
capsules containing the above mentioned L. 
gasseri DSM 14869 and L. rhamnosus DSM 14870. These strains were originally 
isolated from Scandinavian women and were proven to be most effective in adhesion to 
vaginal epithelial cells, growth, acid and H2O2 production. The capsule contains 10
8 
- 
10
9 
colony forming units (CFU) of each Lactobacillus strain per capsule. 
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1.5    HIV-1 infection 
 
In 1982, the term AIDS was introduced by U.S. Centers for Disease control and 
prevention, to name the disease responsible for ongoing epidemic. Thereafter in 1983, 
HIV was for the first time isolated by Luc Montagnier and his team in France (85), 
which was shown by Robert Gallo and his team in the USA to be the cause of AIDS 
(86). HIV-1, the first isolated virus, has caused infection worldwide. The virus 
establishes infection by interacting primarily with the host CD4 T-lymphocyte (87), 
macrophages and dendritic cells that express CD4 and CCR5/CXCR4 cell receptors. 
 
 
The transmission of HIV-1 occurs by direct blood-to-blood contact or contact with 
contaminated blood products or syringes. However, unprotected heterosexual 
intercourse has remained the major cause of HIV-1 transmission and the region with 
the highest HIV prevalence is Sub-Saharan Africa. According to a global report in 2011 
by UNAIDS, sub-Saharan Africa represents 69% of all HIV infections worldwide (Fig. 
2) (88). 
 
 
 
 
 
In the case of sexual transmission of HIV-1, the mucosa is the site of infection for the 
virus. In the vagina, the mucous membrane of the female genital tract, which is mainly 
composed of multilayers of stratified epithelia, offers a good barrier to the virus. The 
mucus with pH around 4 immobilizes virus-like particles and prevent them from 
causing infection (89). Lactobacilli colonizing the vagina environment with acid 
production and exhibit other protective properties. In the absence of these beneficial 
lactobacilli, women who suffer from BV become vulnerable to vaginal infections and 
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infection by HIV-1. Vaginal epithelia abraded by bacterial vaginosis, genital infections 
(eg, HSV-2 and syphilis), use of intravaginal preparations for “dry sex” and sexual 
trauma can critically increase the rate of HIV transmission (90). It has been shown that 
the lack of commensal lactobacilli in the vagina leads to increased risk of acquiring 
HIV infection in women and transmission to their male partners (91,92). These 
conditions highly favor the occurrence and transmission of HIV-1. 
 
 
1.5.1    Strategies against HIV-1 transmission 
 
Zidovudine was the first antiretroviral drug to be introduced in 1987 followed by 
didanosine and zalcitabine. To overcome the risk of developing drug resistance and to 
minimize viral replication, two or more drugs are used together in combination which is 
of high clinical relevance and benefit (93). This therapy is named as highly active 
antiretroviral therapy (HAART) and the drugs prescribed belong to different classes. 
There are several different antiretroviral drugs available today for clinical use based on 
different stages of HIV life cycle. They are of five different classes; entry inhibitors (eg. 
maraviroc and enfuvirtide), nucleoside analog reverse transcriptase inhibitors (NRTI) 
(eg. deoxythymidine, zidovudine, stavudine, tenofovir), non-nucleoside analog reverse 
transcriptase  inhibitors  (NNRTI)  (eg.  nevirapine,  delavirdine,  efavirenz,  and 
rilpivirine), integrase inhibitors (eg. raltegravir) and protease inhibitors (PI) (eg. 
atazanavir, darunavir, ritonavir, indinavir, lopinavir, nelfinavir) all with different modes 
of action.  Antiretroviral therapy was successful in rapidly reducing the viral load and 
reviving the host CD4 T-cell count (94,95). However, lack of complete normalization 
of T-cell levels upon treatment (96), complexity related with the use of antiretroviral 
drugs and side effects (97) are still major challenges. 
 
 
Another branch of emerging anti-HIV drugs are microbicides. Microbicides are 
compounds that can be applied in vagina or rectum to protect against HIV-1 and other 
sexually transmitted infections. To prevent new cases of HIV-1 infection concept of 
“ABC” is being highly promoted which according to UNAIDS can be defined as 
abstinence from sex, being faithful to your sexual partner and condom use. However in 
male dominated societies this might not function and hence a female controlled 
microbicide formulation active against HIV-1 could prove effective. 
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1.5.2    Microbicides 
 
Microbicides can act in different ways and also have varying degrees of specificity 
(98,99). The first generation of microbicides was broadly reactive, but non-specific in 
its activity. Nonspecific microbicides consist of buffering agents, detergents or 
surfactants that include nonionic, anionic or cationic compounds.  For  example,  
formulations  like  cellulose  sulphate,  Carraguard
   
(a synthetic naphthalene 
sulfonate polymer), and PRO2000
  
(containing the polyanion carrageenan) provide a 
physical barrier that prevents pathogens from interacting with host cells. So far mostly 
non-specific microbicides, such as surfactants and polyanions, have completed phase 
III clinical testing and none has demonstrated clear statistical evidence of protection. 
These failures could be conquered by developing microbicides with increasing 
specificity and well-defined mechanisms of action that might be less prone to 
unwarranted adverse effects on the integrity of the natural barriers to transmission. The 
life cycle of HIV provides a number of points at which a microbicide could 
theoretically prevent infection. Each step of the virus entry pathway and replication is a 
potential target for novel inhibitors. The CD4 binding site (CD4bs) and the co-receptor 
binding site (CoRbs) of gp120 as well as gp41, which mediate fusion, are therefore 
attractive targets for various kinds of microbicides (100,101). In a recent clinical trial in 
South Africa, tenofovir an NRTI in a microbicide gel formulation was found to lower 
the HIV-1 incidence rate in treatment group (102). The development of antibodies that 
target the conserved envelop epitopes (gp120) also clearly represent a desirable 
approach to block viral transmission. A few human monoclonal antibodies (mAbs) 
against gp120 (such as b12 or VRC01) that broadly neutralize diverse HIV-1 strains 
have been isolated from HIV-1–infected patients (103,104). Vaginally administered b12 
and VRC01 mAbs have also been shown to protect against mucosal SHIV challenge in 
animal models, suggesting the use of antibodies as potential vaginal microbicides 
(105,106). 
 
 
1.6    VHH 
 
VHH are the variable domain of llama heavy chain only antibody naturally found in the 
members of Camelidae family (Fig. 3). It consists of a single immunoglobulin domain 
and is the smallest naturally occurring antigen-binding molecule known to date (107). 
VHHs exhibit several advantages over conventional antibodies, as they are markedly 
more acid and heat resistant and, being formed by a single polypeptide, are easier to 
express in a functional recombinant form. These properties make VHH suitable for 
10  
therapy at mucosal sites such as the vagina where the acidic environment can limit the 
functionality of conventional antibodies. In addition, owing to their naturally longer 
CDR2 and CDR3 regions, llama VHH antibody fragments are superior at accessing 
clefts such as active sites of enzymes and canyons on virus capsids. VHH have low 
immunogenicity and they are unlikely to exhibit untoward side effects during chronic 
application (108–110). 
 
 
 
 
1.6.1    VHH as neutralizing antibody molecules against pathogens 
 
In 2006, Baral et al. and van der Vaart et al. generated broadly cross-reactive and 
protective VHH fragments targeting a number of trypanosome isolates and globally 
prevalent strains of rotavirus (111,112). VHH, being one-tenth the size of conventional 
antibodies, are expected to diffuse more readily inside the crevices at the interface 
between a virus and its target cells, thus blocking infection. 
 
 
Thereafter, Forsman et al. in 2008 isolated and characterized VHH fragments reacting 
with the CD4 binding sites of gp120, which were broadly neutralizing HIV-1 subtypes 
(113). This study showed that the VHH antibodies could be generated against HIV-1 in 
llamas, which are specific against CD4bs on gp120 but the VHH generated against 
HIV-1 displayed limited neutralization. However, the same group was able to select a 
VHH “J3”, which neutralized 96 out of 100 tested HIV-1 strains belonging to subtypes 
A, B, C, D, BC, AE, AG, AC, ACD, CD, and G with low IC50 values (median) 
ranging between 0.32 to 4.42 µg/ml   (112). In comparison with the monoclonal 
antibody VRCO1, that neutralized 88.4% of the 69 viral strains tested (104), VHH J3 
was  more  potent  neutralizing  94.2%  of  the  same  set  of  69  viruses.  Thus,  VHH 
represents a novel tool for prophylaxis and therapy against HIV-1 (114). 
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1.7    Lactobacillus mediated delivery of VHH antibody fragments against HIV-1 
 
A major impediment to passive administration of specific microbicides is to provide a 
practical and continuous delivery of the product. To date the largest number of 
intravaginal drug delivery systems for microbicides are in the form of creams, gels, 
suppositories or intravaginal rings (115). Although commonly used for topical 
intravaginal delivery of microbicides, gels or creams must be applied immediately 
before sex. Vaginal rings also have disadvantages as insertion is unpleasant for some 
women and it may cause vaginal irritation and discharge. Since some exogenously 
administered lactobacilli were shown to colonize the vaginal tract and restore a normal 
VMB, an attractive idea is to use lactobacilli as vectors for in situ delivery of antibody 
fragments against HIV in the vaginal tract. Once administered, the lactobacilli would 
persist for days or weeks in the vaginal tract allowing production of microbicides in 
situ. This approach requires the use of lactobacilli that can persist in the vaginal tract, 
which, also explains why we selected lactobacilli that can colonize the vagina and 
attempted to improve the colonization in paper I and II. 
 
 
Efforts have been made to design a Lactobacillus strain (L. jensenii 1153) to secrete the 
first two extracellular domains of human CD4 (2D CD4), RANTES (a natural ligand of 
CCR5) and cyanovirin-N (a carbohydrate binding protein) isolated from cyanobacteria 
(116,117). Thereafter a vaginal isolate L. reuteri RC-14 was also modified to produce 
the HIV entry and fusion inhibitors 2D CD4, MIP-1, and T-1249 (118). The 
microbicides produced by lactobacilli were shown to neutralize HIV-1 in vitro. 
Lactobacilli have previously been engineered and used for delivery of functional VHH 
antibody fragments against rotavirus and Lactococcus phages (119,120). These in vitro 
studies prove the concept of expressing functional VHH antibody fragments that can 
neutralize pathogens. These antibodies were expressed using our model strain L. 
paracasei BL23. Similarly, vaginal lactobacilli eliciting probiotic properties could be 
engineered to produce VHH antibody fragments as a prophylaxis against HIV-1. A 
better understanding of the species composition and ecology of bacterial ecosystems is 
required for developing engineered probiotic lactobacilli and Lactobacillus based 
prophylaxis against BV and HIV in developing countries. Therefore, we have identified 
the cultivable vaginal Lactobacillus species in South African women (paper III). 
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2 AIMS 
 
 
The aims of this thesis were to assess the clinical interventions (antimicrobials in 
combination with lactobacilli) for long-term cure of vaginal infections such as bacterial 
vaginosis (BV) and vulvovaginal candidiasis (VVC), and to successfully produce a 
functional VHH antibody fragment against HIV in lactobacilli for future applications. 
The specific aims were: 
 
 
  To  characterize  human  vaginal  lactobacilli  and  to  evaluate  an  extended 
antibiotic treatment regimen together with adjuvant lactobacilli for improving 
the cure rate of BV. 
 To investigate the colonization by lactobacilli and clinical outcome in women 
receiving prolonged treatment with EcoVag
® 
lactobacilli, in combination with 
antibiotic or anti-fungal treatment. 
  To  identify  the  cultivable  vaginal  Lactobacillus  species  in  South  African 
women and to compare that with the Lactobacillus microbiota identified in 
European population. 
  To  express  a  neutralizing  VHH  antibody  fragment  against  HIV-1  in  L. 
paracasei BL23 (a model strain). 
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3    MATERIALS AND METHODS 
3.1    Lactobacilli used for treatment (Paper I and II) 
 
In paper I, Lactobacillus strains isolated from healthy Swedish women (80) were 
characterised and nine were selected for the clinical trial. The lactobacilli were 
fermented, lyophilised, and dispensed as a mixture of three different strains 
(10
9
/capsule) in gelatin capsules according to GMP standard (Gruppo Clerici SACCO 
SS.r.l., Cadorago Italy together with Bifodan A/S, Hundested, Denmark). Other strains 
from commercial products, currently used for treatment of BV, were also tested. These 
strains include L. gasseri (Lba EB01-DSM 14869) and L. rhamnosus (Lbp PB01-DSM 
14870)  contained  in  the  commercially  available  EcoVag
®   
vaginal  capsules  (10
8
 
 
CFU/capsules) (Bifodan A/S, Denmark). Capsules containing a mixture of EcoVag
® 
strains plus L. gasseri DSM 15527, were also tested. These Lactobacillus strains were 
initially isolated from healthy women in Norway and characterised by Bifodan. The 
second probiotic preparation used was LaciBios
® 
(oral capsules containing 
Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (around 10
9
/capsule)). 
These  Lactobacillus  strains  have  been  described  in  the  studies  by  Reid  and 
collaborators (81,121). In paper II, only the EcoVag
® 
vaginal capsules from Bifodan 
were used for the treatment. 
 
 
3.2    Study population (Paper I-III) 
 
In Paper I, the study was conducted at an outpatient private gynaecological clinic in 
Drammen, Norway from January 2007 until January 2011. A total of 76 patients were 
included in the study. In paper II, the first clinical trial including patient with BV was 
conducted in an outpatient private gynecological clinic in Drammen, Norway from July 
2009 until January 2011 and the second trial including both patients with BV and yeast 
infection was carried out in Skövde, Sweden. A total of 10 women in the first and 26 
women in second clinical trial have been included. In both studies, women included 
were regularly menstruating women, 18 years or older, with normal gynaecological 
status, not pregnant or breast-feeding and without signs of other genital tract infections. 
Exclusion criteria were patients with hormonal IUD without regular menstruation; 
women infected with Chlamydia trachomatis, or Trichomonas vaginalis, or with a 
clinical Candida infection. 
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In paper III, forty premenopausal and HIV uninfected black women aged 18–44 years 
with or without BV were recruited for the study. Study participants were randomly 
selected among women who visited the Perinatal HIV Research Unit (PHRU) in Chris 
Hani Baragwanath Hospital Inclusion criteria were their willingness to provide the 
informed consent, passing the assessment of understanding, BHCG negative status 
(non-pregnant) and belonging to a low risk group for HIV acquisition. The women 
were non-menstruating and not taking antibiotics at the time of sample collection. 
 
 
3.3    Clinical method (Paper I and II) 
 
In paper I and II, women had a routine gynecological examination with a non- 
lubricated speculum and a vaginal ultrasound at inclusion. A sample of vaginal 
secretion was analysed for vaginal pH using special pH strips (range 3.8-5.0). The 
diagnosis of BV was based on Amsel criteria (45), i.e. fulfilling at least 3 of 4 criteria; 
thin homogenous discharge, vaginal pH above 4.5, positive amine test, and presence 
of clue cell during microscopical investigation using a phase contrast microscope. A 
vaginal sample was also taken and air-dried for Hay/Ison scoring. 
 
 
In  paper  II,  yeast  infection  was  diagnosed  on  the  basis  of  clinical  examination 
showing thick vaginal discharge with a pH of less than 4.5 and a wet smear & KOH 
smear confirming the presence of alkali resistant blastospores or hyphae of Candida 
albicans using a phase contrast microscope seen on magnification of 400 times. At 
inclusion,  vaginal  samples  were  also  tested  for  Chlamydia  trachomatis  infection 
using strand-displacement amplification (CT amplified DNA assay; Becton- 
Dickinson) according to the local laboratory routine. Samples for Neisseria 
gonorrhoeae culture were only taken when deemed clinically motivated. In paper III, 
BV was diagnosed on the basis on Nugent score. 
 
 
3.4    Treatment of BV and yeast infection (paper I and II) 
 
In paper I, women in the BV group were given a seven days course of daily 2% vaginal 
clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral 
clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd) and a 5 days 
course of vaginal metronidazole (Zidoval gel 75 g, Meda AS, Norway) was given after 
first and second menstruation. Immediately after clindamycin and the first 
metronidazole treatment, vaginal Lactobacillus capsules were given for 5 days (Fig 
4A). Oral clindamycin treatment was also given to the patient's sexual partner (122). 
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In paper II, the first clinical trial was designed with one group of 10 women diagnosed 
with BV. The treatment with antibiotic and lactobacilli was similar but women were 
given only one course of metronidazole instead of two (after the first menstruation). In 
the second trial (trial II), 10 women were recruited in each of the three different groups 
which are as follows: 1- women with BV receiving antibiotics and lactobacilli (Fig 4B), 
2- women with yeast infection receiving anti-fungal drug and lactobacilli (Fig 4C) and 
 
3- women with yeast infection receiving only the anti-fungal drug. Women with BV 
received similar antibiotic treatment as in the first trial and a prolonged treatment with 
vaginal lactobacilli. After each antibiotic course, EcoVag
® 
capsules were given for 10 
days (instead of 5) and after the second menstruation once every week for the next four 
months. 
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Women with Candida infection were given a 28 day course of Fluconazole 50 mg 
every day followed by vaginal EcoVag
®  
capsules for 10 days. After the first 
menstruation, EcoVag
® 
capsules were given again for 10 days along with a weekly 
course of 200 mg Fluconazole for two months. This was followed by a third course of 
Fluconazole, where women were given 200 mg of the drug once every two weeks for 
next six months along with lactobacilli once every week for four months. A group of 
women with Candida infection are being treated only with Fluconazole for controlling 
the effect of lactobacilli in the Candida treatment protocol. 
 
 
3.5    Sample collection (Paper I-III) 
 
In paper I and II (trial I), after every menstruation the patients took a self-swabbed 
vaginal culture whereas in paper II (trial II) vaginal swab sample was taken twice every 
month (on day 7 and day 21). In paper III, swab samples were taken at a single time 
point. In all the studies, vaginal swabs were collected in Amies agar gel medium with 
charcoal (Copan Venturi Transsystem® Copan Diagnostics, Italy). A glass smear was 
also taken which was air dried and sent in a sealed envelope along with the swab to our 
laboratory in Karolinska Institutet. The smear was gram stained for BV scoring. 
 
 
3.6    Isolation of Lactobacillus from swab samples (Paper I-III) 
 
Upon arrival, swabs were streaked onto Rogosa agar, blood agar plates and de Man- 
Rogosa-Sharpe (MRS) agar plates. Plates were incubated for 48 hours at 37°C in an 
incubator in anaerobic condition using BD GasPack™ EZ gaz generating systems 
(Becton, Dickinson and Company, Sparks, MD) and the colonies with Gram positive 
rods were grown in MRS broth medium for preparing the frozen stocks (15%) and 
genomic DNA isolation. Four to eight colonies were picked per sample. 
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3.7 Identification and genotyping of the isolated species (Paper I-III) 
Lactobacillus species were identified by amplifying and sequencing the complete 16S 
rRNA  gene  (1.5  kb).  The  obtained  sequences  were  then  subjected  to  nucleotide- 
nucleotide BLAST using BLASTN (http://www.ncbi.nlm.nih.gov/) and subsequently 
compared to the 16SrRNA sequences of typed strains to validate the results (papers I to 
III). Genotyping of the isolated Lactobacillus species in paper I and II was performed 
initially by using PCR amplification of the bacterial repetitive extragenic palindromic 
DNA sequences  (REP-PCR) and  then  distinguishing  the typed  isolates  further  by 
performing RAPD (Rapid Amplified Polymorphic DNA)-PCR. 
 
 
3.8    Hydrogen peroxide (H2O2) production test 
 
Lactobacillus isolates were streaked onto a 20 ml MRS agar plate containing 0.25 
mg/ml 3,3’, 5,5’-tetramethylbenzidine (TMB) and 0.01 mg/ml of horseradish 
peroxidase (HRP) (Sigma-Aldrich). Plates were incubated in anaerobic condition using 
the BD Gas Pack™ anaerobic container system for 72 hours and were exposed to air 
for 30 minutes before scoring them for blue coloration. HRP generates O2  from any 
H2O2 produced by the lactobacilli, which in turn oxidizes the TMB substrate to form a 
blue pigment. On the basis of the blue coloration, isolates were scored for H2O2 
production as 0 for no blue coloration, 1 for light blue, 2 for moderate and 3 for dark 
blue coloration. 
 
 
3.9    Statistical analysis 
 
In paper I, "Time from treatment to relapse" has been calculated in months and was 
used to explore differences in time to relapse between groups by survival analysis 
with Kaplan Meier procedure. A logistic regression analysis was performed and an 
Odds ratio (OR) with 95% confidence interval (CI) was calculated. All comparisons 
both between and within groups was performed two-tailed with a significance level of 
5%. All the analyses in this study were performed in PASW (SPSS) v.18 and in 
accordance with the principal of intention to treat (ITT). In paper II, the difference in 
frequency of isolation of any lactobacilli or L. rhamnosus DSM 14870 and L. gasseri 
DSM 14869 was compared by Fisher exact test. Two-tailed P values less than 0.05 
were considered statistically significant. Odds ratio to analyze association between 
change of partner and relapse of BV was calculated at 95% confidence interval using 
contingency table analysis. 
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In paper III, Fisher’s exact test was performed to test the relation between BV status 
(normal   microbiota   vs.   BV)   and   the   presence   of   any   lactobacilli,   specific 
Lactobacillus species and high/low H2O2-producing lactobacilli. Two-tailed P values 
less than 0.05 were considered statistically significant. All the comparisons in Paper 
II and III were performed with GraphPad Prism 4 software (GraphPad Software, Inc., 
La Jolla, Ca). 
 
 
Methods applied in Paper IV 
 
 
3.10  Bacterial strains, plasmids and growth conditions 
 
E. coli DH5α (Invitrogen, Carlsbad, CA) was grown on Luria-Bertani (LB) plates at 
 
37°C or in LB broth with 220 rpm orbital shaking at 37°C. L. paracasei BL23 
(previously known as L. casei or L. zeae ATCC 393 pLZ15
-
)  (123) was grown in 
Lactobacilli MRS agar (Difco, Becton Dickinson, Sparks, MD) plates at 37°C 
anaerobically using BD GasPack™ EZ gaz generating systems (Becton, Dickinson and 
Company) or in MRS broth without shaking. VHH fragments were expressed in 
Lactobacillus under the high activity APF promoter in the expression vector pAF100 
and pAF900 (124). When appropriate, the concentrations of antibiotics used were 100 
µg/ml ampicillin or 300 µg/ml erythromycin for E. coli transformants and 5 g/ml 
erythromycin for L. paracasei transformants. 
 
 
3.11  VHH J3 
 
A llama was immunized with a mixture of gp140 trimers derived from a subtype BC 
HIV-1 strain CN54 (gp140 CN54) and a subtype A strain 92UG037 (gp140 UG37) and 
VHH J3 was selected directly from the phage library for their ability to neutralize HIV- 
1 pseudovirus as described by McCoy et al (114). VHH J3 was the best candidate 
neutralizing 96% of the 100 tested HIV strains and was hence chosen for expression in 
lactobacilli. 
 
 
3.12  Expression of VHH in L. paracasei 
 
The gene encoding J3 was cloned in two different expression cassettes, pAF100 which 
allows the protein to be secreted out from lactobacilli in the culture supernatant 
(secreted version) and pAF900 which mediate display of the protein on cell surface 
(anchored version) (Fig. 5) (124). The J3 VHH was fused to an E-tag at C-terminal 
before the stop codon in the secreted version and between the VHH gene and prtP 
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anchor sequence in anchored version for detection and purification of the protein. We 
modified our original expression cassette by removing the extra N-terminal sequence 
present in between the signal peptide and cloned VHH. The plasmids were transformed 
into L. paracasei BL23 (123) by electroporation as described previously generating L. 
paracasei mJ3-pAF100 and L. paracasei mJ3-pAF900. 
 
 
 
 
 
3.13  Western blotting 
 
The L. paracasei BL23 transformants were grown in MRS broth with 5 µg/ml 
erythromycin until an OD600 of 1.0. The cultures (1 ml) were centrifuged at 8000 rpm 
for 5 minutes (min) to separate the cell pellet and supernatant. The supernatant was 
filter sterilized, pH adjusted to 7.0, mixed with Laemmli buffer in 1:1 ratio and boiled 
for 5 min. The cell pellet was washed twice with PBS, re-suspended in 100 µl Laemmli 
buffer and boiled for 5 min. The cell extract was centrifuged at 13,000 rpm for 5 min to 
remove cell debris and the supernatant containing the soluble proteins was recovered. 
Supernatant and cell extract were run on SDS –polyacrylamide gel at 170 volts and the 
proteins were transferred onto a nitrocellulose membrane (Hybond-ECL, GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). The membrane was blocked with 
PBS-T (PBS with 0.05% (v/v) Tween 20 + 5% (w/v) milk powder) and successively 
incubated with mouse anti E-tag antibody (1µg/ml, Phadia AB, Sweden) at room 
temperature (RT) for 2 hours (h) and HRP (horse radish peroxidase) labeled goat anti- 
mouse antibody (DAKO A/S, Glostrup Denmark) at RT for 1 h. The signal was 
detected by chemiluminescence using ECL Plus
TM  
Western Blotting detection system 
 
(GE Healthcare). 
 
 
 
3.14  Enzyme linked immunosorbent assay (ELISA) 
 
96 well microtiter plates were coated with 50 µl Bal.26 gp120 (NIBSC, Hertfordshire, 
UK) at 2 µg/ml in PBS overnight (o/n) at 4°C. Plates were subsequently blocked with 
1% BSA (in PBS containing 0.05% Tween 20, PBS-T) for 4-6 h at RT. After washing 
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the plates with PBS-T, dilutions of Lactobacillus culture supernatants containing 
secreted VHH and Lactobacillus purified VHH were added and the plates were 
incubated at 4°C o/n.  E. coli purified VHH J3 (114) was used as positive control for 
binding.   Supernatant from L. paracasei pAF100-ARP1 producing secreted VHH 
against  rotavirus  was  used  as  a  negative  control  (124).  Plates  were  subsequently 
washed three times with PBS-T and mouse anti E-tag antibody was added at 1 µg/ml in 
blocking solution followed by incubation at RT for 2h. Plates were then washed three 
times with PBS-T and incubated with alkaline phosphatase (AP) conjugated rabbit anti- 
mouse antibody at 1/1000 (Dako A/S, Glostrup Denmark) in blocking solution. 
Following additional 1 h incubation at RT, the plates were washed thrice with PBS-T 
and once with PBS. After the washes, 100 µl of diethanolamine buffer (1M, pH 10.0) 
containing 1mg/ml p-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO) was added 
and the absorbance was read after 10-30 min at 405 nm in a Varioskan Flash (Thermo 
Scientific, Waltham, MA). 
 
 
3.15  Purification of the VHH and quantitation 
Purification of the secreted VHH was performed by using a HiTrap
TM 
anti E-tag 
Column (GE-Healthcare) according to the manufacturer’s instructions. Eluate was 
concentrated on Amicon ultra-3K centrifugal filter (Millipore, Carrigtwohill, County 
Cork, Ireland). 
 
 
3.16  BCA assay for protein quantitation 
The concentration of purified VHH was determined using the Micro BCA
TM  
Protein 
 
Assay Kit (Pierce, Rockford, IL) with bovine serum albumin (BSA) as a standard. 
 
 
 
3.17  Flow cytometry 
 
Flow cytometry was used for detection of anchored VHH on Lactobacillus surface and 
for its binding to HIV-1 envelope glycoproteins. For detection of J3 on the surface of 
lactobacilli 50 µl of the Lactobacillus cultures of J3-pAF900 construct grown to an 
OD600 of 1.0 in MRS were harvested by centrifugation (8000 rpm, 3 min) and washed 
three times with 500 µl PBS. Bacteria were re-suspended in 50 µl PBS with 1% BSA 
(PBS-BSA) and incubated on ice for 30 min sequentially with 50 µl anti E-tag antibody 
(10 µg/ml) and 100 µl fluorescein isothiocynate (FITC) conjugated anti-mouse 
immunoglobulins (diluted 1/200) (Jackson Immunoresearch Laboratories, West Growe, 
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PA), all diluted in PBS-BSA. Bacteria were washed with 500 µl PBS between all three 
incubations. 
 
 
To test binding of surface anchored J3 to HIV-1 glycoproteins, 50 µl of L. paracasei- 
mJ3-pAF900 construct were harvested and washed three times in PBS. Bacteria were 
incubated on ice for 30 min with biotinylated Bal.26 gp120 (NIBSC, Hertfordshire, 
UK) and CN54 gp140 (Polymun Scientific, Klosternevburg, Austria) at concentration 
of 10 µg/ml followed by incubation with streptavidin PE (diluted 1/200) for 30 min on 
ice. Glycoproteins were biotinylated using EZ-LinkTM Sulfo-NHS-LC-Biotinylation 
kit (Thermo Scientific) as per the manufacturer’s protocol. Non-transformed L. 
paracasei BL23 and L. paracasei pAF900-ARP1 producing surface anchored VHH 
against rotavirus were used as a negative control (124). 
 
 
3.18  In vitro neutralization assay 
 
Lactobacillus produced VHH was tested for neutralizing activity in vitro using the 
TZM-bl luciferase assay against a range of HIV-1 pseudoviruses. For the Lactobacillus 
secreting VHH, VHH purified from the supernatant was tested. For the surface 
anchored lactobacilli, the bacteria were used for pre-absorption of the virus before 
inoculation of the target cells. The TZM-bl cells were cultured in DMEM (Gibco BRL 
Life Technologies) containing 10% heat-inactivated FBS µg/ml gentamicin (Sigma). 
Cell monolayers were disrupted at confluency by treatment with 0.25% trypsin in 1mM 
EDTA. Envelop (Env) pseudotyped viruses were obtained by co-transfecting the Env 
plasmid with pSG3∆Env (125) using FuGENE transfection reagent (Roche) as 
previously described (126). Neutralization was measured by a reduction in luciferase 
gene expression after single-round of infection of TZM-bl cells with Env-pseudotyped 
viruses (126). VHH IC50 titers were calculated as the reciprocal viral dilution (ID50) 
causing 50% reduction of relative light units (RLUs). 
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4    RESULTS 
4.1    Paper I 
 
Most women experience BV and many of them suffer from relapses. In order to reduce 
the frequency of relapses and to find out if an extended antibiotic treatment against 
bacterial vaginosis (BV) together with adjuvant lactobacilli treatment could cure BV. In 
this study 63 women diagnosed with BV were included and were offered a much more 
aggressive treatment than given in current clinical practice with repeated clindamycin 
and metronidazole treatment and vaginal Lactobacillus administration. Both newly 
characterized and commercially available Lactobacillus strains were used for vaginal 
administration. 
 
 
The women receiving EcoVag
® 
were colonized by L. rhamnosus 14870 in 6 out of 8 
cases (75%). The strain persisted more than 2 months in three patients, i.e. about 2 
weeks after stopping its administration and until month 3 and 5 in two other patients 
(one and three months after stopping the treatment respectively). Of the women 
receiving the characterised lactobacilli isolated from Swedish women (Group 1 to 3), L. 
crispatus strains (4R5, 8R6 and 23B33) were the ones showing the best colonization. 
Although colonizing a lower proportion of women (around 33%), L. crispatus 4R5 
(Group 1), L. crispatus 23B33 (Group 2), and L. crispatus 8R6 (Group 3) persisted 
until month 6 in 7 out of 9 women colonized by one of these strains i.e. 4 months after 
stopping the treatment. However, no significant difference was observed in the cure 
rate depending on which Lactobacillus strain was given and whether the women were 
colonized by lactobacilli. The patients were followed as long as possible or until the 
relapse. The cure rates obtained after month 6, 12 and 24 were 74.6%, 65.1% and 
55.6%. One of the most noticeable observations in the study was occurrence of relapse 
of BV in women after having a new sexual partner (Odds ratio of 9.3). To conclude, 
aggressive treatment with antibiotics combined with vaginal administration of 
lactobacilli gave a long term cure. 
 
 
4.2    Paper II 
 
Paper II represents two trials which were conducted in order to confirm results of paper 
I and to improve Lactobacillus colonization and BV treatment. We also tested for the 
first time, a combination of EcoVag
®  
and anti-fungal for treatment of recurrent yeast 
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infection and evaluated if lactobacilli can colonize women when the microbiota is not 
disturbed by antibiotics. 
 
 
In trial I, 10 women diagnosed with BV were recruited and given the combination 
treatment with antibiotics and lactobacilli as mentioned before (methods, section 3.3.). 
In trial II, both women with BV and yeast infection were recruited. A similar treatment 
with clindamycin and metronidazole was given for BV but the Lactobacillus dose was 
increased. EcoVag
® 
vaginal capsules were given for 10 days after every antibiotic 
treatment and after the second menstruation once every week for four months. Women 
with yeast infection also received a similar Lactobacillus treatment along with 
fluconazole. Another modification in the protocol was that the swab samples were 
collected twice every month on day 7 and 21 as the level of lactobacilli may vary 
during the menstruation cycle. 
 
 
In trial I, nine of the 10 women treated for BV got colonized by either of the EcoVag
® 
Lactobacillus strains during the study. In eight women, EcoVag
® 
strains persisted for at 
least two weeks after stopping the treatment. In three women, either of the strains was 
identified at month four (two months after the treatment was stopped) and persisted 
until month five (three months after the treatment) in two of them. L. gasseri DSM 
 
14869 was more frequently isolated than L. rhamnosus DSM 14870 (17 vs 9 out of 42 
samples) but the difference was not significant (P=0.098). The cure rate after month 6 
was 50 % with four women cured and four with a relapse of BV. Two women did not 
complete the sixth month follow up. 
 
 
In trial II, either of the EcoVag
® 
strains was identified until month five in 5 of the 10 
women (71%). L. gasseri was the dominant colonizer in this group colonizing seven 
women at some stage during the study and was regularly isolated in two women out of 
seven until month six. L. rhamnosus was isolated from five women but more 
sporadically. In three women, both the EcoVag
® 
strains were found to colonize 
individually at different sampling points. Some of the interesting observations were: - 
1-  EcoVag
®  
strains  colonized  women  but  other  Lactobacillus  species  were  seen 
 
colonizing throughout the study; 2- EcoVag
®  
strains were more frequently isolated 
from women that did not have lactobacilli at the start of the study compared to women 
who had lactobacilli at the start of the treatment; 3- No significant difference was 
observed in the frequency of isolation of EcoVag
® 
strains or other lactobacilli between 
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sample 1 (day 7) and sample 2 (day 21). 4- A comparison of both trial I and II shows 
that colonization by EcoVag
® 
lactobacilli in women with BV did not improve 
significantly upon increasing the dose. The cure rate for BV group was 66.7% and 
62.5% after month 6 and 12. Three women had a relapse after having a new sexual 
partner. 
 
 
The frequency of isolation of any Lactobacillus species during the course of the study 
was associated with cure of BV in trial I and II whereas, the frequency of isolation of 
EcoVag
® 
strains was significantly associated with the cure of BV in trial II only. As 
previously observed, a change in sexual partner was associated with relapse of BV with 
an Odds ratio of 77 (95% CI: 2.665 to 2225). 
 
 
In the second group of women with Candida infection, EcoVag
® 
strains were isolated 
from 8 out of 9 (89%) women at some time point during the study but the Lactobacillus 
microbiota was dominated by non EcoVag
® 
Lactobacillus strains. L. rhamnosus DSM 
14870 was isolated from six women and L. gasseri DSM 14869 from five women. L. 
rhamnosus DSM 14870 could be isolated up to month 5 in three women. Both strains 
could be isolated at some point in three women. Overall L. rhamnosus DSM 14870 and 
L. gasseri DSM 14869 were isolated in 16 (19%) and 10 (12%) out of 86 samples 
respectively. A comparison of both the trials showed that EcoVag
® 
lactobacilli could be 
isolated more frequently in BV patients pretreated with antibiotics (41 out of 86 
samples, 48%) than from Candida infected patients pretreated with anti-fungal drugs 
(24 out of 86 samples, 28%) (P<0.05). The cure rate for VVC was 100% after 6 months 
and 87.5% after 12 months. 
 
 
 
4.3    Paper III 
 
The  vaginal  microbiota  has  been  extensively  studied  in  populations  in  western 
countries but less so in African population. Therefore, we conducted a project in South 
Africa to study the vaginal microbiota in a group of 40 women from Soweto. Vaginal 
swab samples were collected and analyzed for the presence and identification of 
Lactobacillus species, and the VMB was assessed by Nugent scoring using the vaginal 
glass smears. Lactobacilli were identified in 19 out of 21 women harbouring a normal 
vaginal microbiota, in three out of five women with intermediate microbiota and in 
eight out of 14 women with BV. The most commonly identified Lactobacillus species 
were L. crispatus, L. iners, L. gasseri, L. vaginalis and L. jensenii isolated from 10 
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(33%), 8 (27%), 7 (23%), 5 (17%) and 5 (17%) respectively. Importantly, L. crispatus 
was isolated only from women with a normal vaginal microbiota whereas the other 
species were isolated from women both with and without BV. Microscopical 
examination of the smears revealed that in this cohort, clue cells were only observed in 
smears with high Nugent scores, thus confirming as association between the presence 
of clue cells and BV. 
 
 
Presence of any lactobacilli and in particular L. crispatus was significantly associated 
with normal vaginal microbiota (Fisher test, normal vs. BV microbiota, P = 0.0386 and 
P = 0.024 respectively) but not the colonization by other Lactobacillus species. The 
isolated Lactobacillus species were characterized for their production of hydrogen 
peroxide (H2O2). Production of H2O2 was observed in the majority of the L. crispatus 
(90%), L. jensenii (86%) and L. vaginalis (80%) isolates and in a lower proportion of 
the L. gasseri isolates (30%). Though the association was not significant, isolates 
producing high levels of H2O2 were more frequently isolated from women having low 
Nugent scores compared to women with high scores. 
 
 
4.4    Paper IV 
 
The variable domain of heavy chain only antibody (VHH) from Camelidae family is 
the smallest known antibody derivative to neutralize pathogens. The VHH J3 eliciting a 
potent and broad neutralizing activity against HIV-1 was expressed in L. paracasei 
BL23 in secreted and anchored form. Expression of VHH J3 was analyzed by western 
blot and bands of the expected size were detected for secreted (15.24 KDa) and surface 
anchored  (39.83 KDa) J3.  Flow cytometry was  performed  to  confirm  the surface 
display and binding of J3 to Bal.26 gp120. VHH J3 expressing cells gave a strong 
signal for both display and binding to the glycoprotein, whereas the non-expresser L. 
paracasei BL23 and L. paracasei producing VHH against rotavirus (ARP1) did not 
bind to gp120. The binding of secreted J3 to HIV-1 gp120 was shown by ELISA. The 
Lactobacillus purified J3, E. coli produced J3 and Lactobacillus expressing surface 
anchored J3 are currently being tested for in vitro neutralization against various HIV-1 
strains. 
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5    DISCUSSION 
Ever since HIV-1 was identified as the causative pathogen of the AIDS epidemic, trials 
till date are continued in order to come up with a vaccine or treatment, which can 
prevent or cure HIV/AIDS. Despite of the success of HAART, HIV-1 is of a major 
concern because of the genetic variability of the virus and associated side effects of 
anti-HIV drugs. Moreover, education, social environment, sexual behavior, availability 
of medical resources and one’s own health affect the rate of HIV incidences majorly. 
Therefore, a combination of different strategies is required to battle HIV-1. The 
prevalence of HIV is highest in Sub-Saharan Africa and it is striking to see that the 
same is also true for BV (51) which points towards a possible link between these two 
diseases. Research findings in this field has established a link between BV and HIV-1 
infection according to which in the absence of lactobacilli and overgrowth of anaerobic 
bacteria, a condition identified in BV, increases the risk of acquiring HIV-1 infection 
and its transmission (17,20,91). BV is one of the most common vaginitis followed by 
VVC that affects women in their reproductive age and these should be addressed with 
high importance. 
 
 
A novel approach towards improving vaginal health and preventing HIV-1 from 
causing infection would be to develop designer probiotic, which is capable of 
colonizing the vagina and programmed for in situ production of microbicide. For this 
purpose VHH antibody fragment is our choice of microbicide. Among sub-Saharan 
African countries, South Africa is still the country most severely affected by HIV/AIDS 
and therefore we aim in the future to test our designer probiotic approach in South 
Africa.  A stepwise development of all the projects and important research findings are 
discussed in this section. 
 
 
Clinical trials in Scandinavia 
 
5.1    Treatment of BV and Lactobacillus colonization 
 
According to a Meta-analysis BV can be treated with metronidazole and clindamycin 
with an expected one month cure rate of 70-80% and 82% respectively (127) which is 
rarely observed in clinical practice. Despite of the success of treatment with antibiotics, 
high recurrence rate is still a problem. Therefore, in order to achieve a long-term cure, 
we designed a study accessing the impact of an aggressive antibiotic treatment with 
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administration of both clindamycin and metronidazole combined with vaginal 
administration of Lactobacillus capsules (paper I). 
 
 
In paper I, five different Lactobacillus formulations were tested in women: EcoVag
® 
capsules containing L. gasseri DSM 14869 and L. rhamnosus DSM 14870, capsules 
containing EcoVag
® 
strains plus L. gasseri DSM15527 and capsules containing three 
different mixtures of three newly characterized strains (paper I). Each mixture of newly 
characterized lactobacilli contains one strain of each of the following species: L. 
crispatus, L. gasseri and L. jensenii.  The antibiotic treatment consisted of one course 
of clindamycin treatment (oral and vaginal) followed by two courses of metronidazole 
vaginal gel. Lactobacillus capsules were given for 5 days after both the clindamycin 
treatment and the first treatment with metronidazole. The obtained cure rate was 74.6% 
and 65.1% after 6 and 12 months respectively, which is higher than in most of the other 
studies (paper I). A similar cure rate was obtained with different preparations of 
lactobacilli administered. Among the strains tested, only three L. crispatus strains and 
L. rhamnosus DSM 14870, could be isolated from the vaginal samples. L. rhamnosus 
DSM 14870 colonized a higher proportion of women than L. crispatus strains (75% vs 
30%) but the later colonized for a longer period (up to four months after the treatment 
was stopped). However, no correlation was found between colonization and cure of 
BV. In comparison to other well-studied probiotic strains, these results present longer 
colonization with given lactobacilli. Previous studies, where vaginal colonization was 
assessed for L. crispatus CTV-05, L. rhamnosus GR-1 and L. fermentum RC-14, 20 to 
40% of the women not treated with antibiotic were colonized for 4-weeks post intra- 
vaginal administration (82,128,129). In another study, vaginal capsules containing a 
mixture of L. gasseri LN40, L. fermentum LN99, L. casei subsp. rhamnosus LN113 
and Pediococcus acidilactici LN23 were administered for five days to women after 
conventional treatment with clindamycin (130). Following the first menstruation after 
Lactobacillus administration, 53% of the women were colonized by any of the five 
strains but only 26% after the second menstruation. In accordance with our results, no 
correlation was found between colonization and the clinical outcome for BV. The 
difference in colonization by the probiotic lactobacilli might depend on factors such as 
the microbiota at enrollment and vaginal intercourse (82). Thus it was clear to us that in 
order to achieve long-term cure and reduce the relapses, an aggressive antibiotic 
treatment combined with lactobacilli provides an opportunity for the VMB to stabilize 
for a long duration. 
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5.2    Modification of the protocol and treatment of BV 
 
Considering the prospects of a vaginal probiotic, especially a microbicide expressing 
lactobacilli for prophylaxis against HIV-1, long-term colonization of the administered 
lactobacilli is of utmost importance. As EcoVag
® 
colonized a higher proportion of 
women, we further designed experiments in order to improve the persistence of 
EcoVag
® 
strains and treatment of BV. It was previously shown that lactobacilli are 
resistant to metronidazole but may be sensitive to high concentrations (131). Therefore, 
in the next trial performed with EcoVag
® 
lactobacilli in BV patients (paper II, trial-1), 
we reduced the metronidazole treatment to one course. This time either of the two 
EcoVag
® 
strains or both colonized 90% of women and persisted up to 3 months after 
the treatment was stopped in 33% of the treated women. In contrast to the paper I, in 
this trial, L. gasseri DSM 14869 was more frequently isolated than L. rhamnosus DSM 
14870, although not to a significant degree (17 vs 9 out of 42 samples, P=0.098). These 
results are slightly better than in our previous study where EcoVag
® 
strains were 
isolated in 75% of the women and in 13% of them, three month after stopping the 
treatment. 
 
 
Later on, Eriksson et al. in 2011 showed that clindamycin could be present in the 
vagina in low concentrations 5 days after the treatment is ceased (132). Since EcoVag
® 
was given for five days immediately after the clindamycin treatment; the presence of 
residual clindamycin might have affected Lactobacillus colonization. Therefore, the 
treatment protocol was further modified (paper II, trial II). We modified the protocol by 
increasing the EcoVag
® 
lactobacilli dose from 5 to 10 days after both the antibiotic 
courses and prolonged the treatment for next four months by giving lactobacilli once 
weekly (Paper II, trial II). We were also interested to note any changes in vaginal 
colonization by EcoVag
® 
lactobacilli during the menstrual cycle and therefore decided 
to collect vaginal samples twice a month. A swab sample and a glass smear were 
collected every month at day 7 and day 21 after menstruation. It has been observed that 
the composition of vaginal microbiota changes during menstrual cycle. After four 
months, 75% of women were identified with EcoVag
® 
in trial II compared to 50% of 
women  colonized  by  EcoVag
®   
in  trial  I  (paper  II).  Hence  the  colonization  and 
 
persistence of EcoVag
® 
lactobacilli slightly improved by increasing the EcoVag
® 
dose 
but not significantly. Furthermore, the frequency of isolation of EcoVag
® 
strains 
throughout the study was similar in both the trials. However, a significant increase in 
colonization  of  other  Lactobacillus  strains  was  observed  in  the  second  trial.  We 
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speculated   that   the   administered   lactobacilli   (EcoVag
®     
capsules)   may   favor 
colonization by other Lactobacillus strains or species by improving the vaginal 
environment although, it might also be because a higher proportion of women harbored 
other lactobacilli at the time of inclusion in trial II (44%) than in trial I (0%). The 
probable colonization resistance offered by the endogenous lactobacilli to the newly 
administered lactobacilli following an antibiotic treatment could explain this. A similar 
finding was described by Antonio et al. where, the presence of endogenous lactobacilli 
decreased colonization by probiotic L. crispatus CTV-05 (82). It has previously been 
shown that the proportion of lactobacilli increases after menstruation and the number of 
other non-Lactobacillus species increases before menstruation (16,133). No difference 
was observed between isolation of EcoVag
® 
strains or other lactobacilli over the cycle. 
 
However, in our study, EcoVag
® 
strains were provided weekly. 
 
 
 
The cure rate at month 6 was 50% for trial I and 66.7% in trial II. This cure rate was 
better than in most published studies but lower than in Paper I (74.6%). This might be 
because only one course of metronidazole was given in the present study instead of two 
(80). The cure rate at month 12 in trial II (62.5%) was however comparable to the one 
previously reported (65.1%). In Paper I, we observed no correlation between isolation 
of EcoVag
® 
strains and cure of BV but we did not consider long-term persistence of 
 
lactobacill.  In  trial  II of  paper 2,  we observed  that  the  frequency of isolation  of 
EcoVag
® 
over the course of the study was associated with cure. Furthermore, in both 
trial I and II, the frequency of isolation of any lactobacilli (EcoVag
®  
strains or other 
Lactobacillus strains) during the treatment period resulted in a better clinical outcome. 
 
 
Overall, a factor which was strongly linked with relapse of BV in paper I and II was the 
change of sexual partner. Whether it is because of increased sexual activity after change 
of partner or because BV may act as a STD associated condition, we can only speculate 
that a stable sexual relationship and use condom might reduce the risk of relapse. 
 
 
5.3 Colonization of EcoVag
® 
lactobacilli in the presence of endogenous 
lactobacilli and cure of VVC 
It was not certain whether the administered lactobacilli would colonize in the presence 
of endogenous lactobacilli and for how long it will persist in the vagina. This is also of 
importance from the microbicide point of view that the engineered lactobacilli are able 
to colonize and persist in women who harbor endogenous lactobacilli. To investigate 
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this, we included a group of women in trial II who were diagnosed with VVC, a 
condition arising from overgrowth of yeast but where lactobacilli are still present. 
These women were treated with fluconazole, which is an anti-fungal drug and not 
expected to kill lactobacilli. Women included in the study had recurrent episodes of 
VVC and were offered an aggressive fluconazole treatment with intent to treat together 
with lactobacilli as described in trial II (paper II). 
 
 
We observed a difference in colonization in BV and VVC treated patients. EcoVag
® 
strains colonized better in women treated with antibiotics for BV than in women who 
were treated with fluconazole for VVC. This could be because of: 1- inefficient 
colonization by EcoVag
® 
lactobacilli in the absence of prior antibiotic treatment and; 2- 
in the presence of certain lactobacilli, which may affect colonization with probiotic 
lactobacilli (134). This is also reflected in our observation that among the women 
treated for VVC, EcoVag
® 
strains were more frequently isolated from women who did 
not have lactobacilli at the start of the study. All the women were cured from of VVC 
at 6 months follow up and 87.5% of these women were still cured at the second follow 
up (from 12-18 months after the initial treatment). Although a few clinical studies have 
presented conflicting results on the use of lactobacilli to reduce recurrence of VVC, 
most of the women in our group remained cured for 12-18 months. Since the 
fluconazole dose given in our study is very high, we question the possible role of given 
lactobacilli in long-term cure of VVC. In order to investigate the efficacy of EcoVag
® 
lactobacilli for vaginal colonization and treatment of VVC, we included a group of 
women  with  R-VVC  who  are  receiving  a  similar  fluconazole  treatment  without 
adjuvant EcoVag
® 
lactobacilli. We are still awaiting the results of this control group. 
 
 
5.4 Which Lactobacillus species colonize South African women? 
Will EcoVag
® 
strains colonize women in Africa! 
The VMB has been studied extensively in Western populations albeit less so in African 
populations. Studies performed in North America, which compared the composition of 
VMB in different ethnic groups, reported the dominance of non-Lactobacillus species 
in black women (14,15). However, studies performed in Africa suggest that the vaginal 
Lactobacillus species colonizing African women are in fact similar to those identified 
in western populations (5,6). It was thus important for us to conduct a study in Soweto, 
South Africa to identify the colonizing vaginal Lactobacillus species and determine 
whether the Lactobacillus microbiota in these women is similar to that identified in 
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western population. If the Lactobacillus species isolated from African women are 
similar to those in America and Europe where probiotic studies have been performed, 
similar strategies utilizing probiotic and engineered lactobacilli could be applied in 
Africa. Furthermore, if needed, the isolated strains could be characterized and tested for 
colonization. The pre-dominant Lactobacillus species identified in our cohort were L. 
crispatus, L. iners, L. gasseri, L. vaginalis and L. jensenii similar to European and 
American women (3,4,135). We also observed that the presence of lactobacilli and in 
particular L. crispatus was associated with normal VMB. None of the women colonized 
by L. crispatus had BV or intermediate microbiota as per the Nugent scores. The role of 
L. crispatus in stabilizing the VMB has been presented by Verstraelen et al. in a 
longitudinal analysis of VMB in 2009 (28). Other Lactobacillus species were isolated 
from women irrespective to the Nugent scores. 
 
 
Various studies have shown an association between colonization by H2O2  producing 
lactobacilli and normal VMB, where lack of such lactobacilli increased the risk of 
developing BV (19,23,25,35). On the contrary, a study by O Hanlon et al. reported that 
the physiological concentrations of H2O2 below 100 millimolar did not kill BV 
associated bacteria (36). In order to find out any association in our cohort we tested the 
isolated lactobacilli for the production of H2O2. In accordance with previous studies 
(136,137), the majority of L. crispatus, L. jensenii and L. vaginalis isolates were H2O2 
producers. The presence of H2O2 producing lactobacilli was higher in women with 
normal VMB, although not to a significant degree which could be due to the small 
sample size and the single sampling point. Moreover, at the time of sample collection, 
behavioral factors that might affect the VMB and the phase of menstrual cycle were not 
noted (except that the women were non-menstruating). Therefore a longitudinal study 
with bigger cohort and by considering all the factors might give more information on 
the association between H2O2 producing lactobacilli and the VMB. 
 
 
5.5    Lactobacilli expressing VHH antibody fragments 
 
Due to their smaller size and single domain nature, VHH are easy to express as 
functional recombinant proteins in bacteria or yeast. As previously reported by our 
group, Lactobacillus produced VHH against rotavirus (ARP1) elicited effective binding 
to and neutralization of rotavirus (112,119). Lactobacilli expressing surface anchored 
ARP1 were able to reduce the viral load and alleviate diarrhea symptoms in a mouse 
pup model. Similarly, a Lactobacillus colonizing the vaginal tract and producing VHH 
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antibody fragment could be used for neutralization of HIV-1. In paper IV, we have 
expressed a VHH against HIV-1 gp140 (VHH J3) in secreted and surface anchored 
form in a model Lactobacillus strain (L. paracasei BL23). The Lactobacillus produced 
VHH were shown to bind to Bal.26 gp120 and are currently being tested for in vitro 
neutralization of HIV-1 strains. An estimated amount of VHH produced by lactobacilli 
is ≈3 μg/ml, which might not be enough for in vivo protection against the virus. On the 
contrary, the advantage of having lactobacilli expressing surface anchored VHH is that 
it offers multiple VHH molecules attached on cell surface thus, increasing the avidity. 
Moreover, the virus once captured by VHH on the Lactobacillus surface would form an 
aggregate, thereby reducing the chance of dissociation of the virus-antibody complex. 
Once aggregated the virus particles would lose their infectivity, reducing the infectivity 
of virus. Compared to the secreted VHH, anchored VHH is expected to be more potent 
taking advantage form the anchored VHH and by being attached on the epithelial cells. 
 
 
The initial phase of infection offers several targets for neutralizing antibodies, which in 
the case of HIV-1 are gp120 and gp41 on the virus whereas CD4 and CCR5/CXCR4 
receptors on the host cell are also potential targets. An advanced approach would be to 
have a polyvalent antibody mix like preparation of lactobacilli expressing VHH with 
different targets thus increasing its avidity. The success of VHH dimers expressing 
lactobacilli at binding to rotavirus and in preventing the development of diarrhea in 
mouse model proved that it is possible to express functional VHH with different 
specificities in dimer form (138). No loss in the expression levels of VHH was noticed. 
Similarly VHH J3, the best candidate, could be coupled with another VHH with a 
different target. The concept would allow us to have custom made lactobacilli 
expressing our key molecules to target various antigens or pathogens (like HSV-2, 
HPV). 
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6    CONCLUSIONS 
 
 
The ultimate aim of these and the future projects is to build an efficacious, economical, 
comfortable and protective strategy for prophylaxis against HIV-1 infections and 
maintain vaginal health. The following conclusions could be drawn from the four 
projects: 
 
 
Paper I and II 
- An aggressive antibiotic treatment combined with administration of EcoVag® 
 
can provide a long lasting cure against BV and VVC. 
 
- A prolonged treatment with EcoVag® lactobacilli together with antimicrobials 
could improve long-term cure against BV and VVC and reduced the rate of 
relapse. 
- The change of sexual partner is associated with relapse of BV. 
 
 
 
Paper III 
 
- The vaginal lactobacilli colonizing South African women is similar to those 
identified in European and American populations. 
- The  presence of lactobacilli,  specifically L.  crispatus,  is  associated  with  a 
normal vaginal microbiota. 
 
 
Paper IV 
 
VHH antibody fragments can be functionally expressed in lactobacilli in both secreted 
and surface anchored forms. 
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7    FUTURE PERSPECTIVES 
Lactobacillus plays an important role in maintaining the vaginal microbiota and has 
been successfully used for improving the vaginal health and for the delivery of 
therapeutic molecules on mucosal sites. Taking into account the recent advances in the 
field of host-microbe interactions, it is irrefutable to accept the importance of a healthy 
host microbiota. Considering these emerging facts, it is of primary importance to 
develop therapeutic strategies targeted to improve vaginal health, which may further 
have a deeper impact on prevention or treatment of sexually transmitted diseases such 
as infection by HIV-1, HSV-2 etc. One of the major thrust areas, which can be 
benefited by the virtue of the same ideology, is the mother-child health. The first 
microbial population, which colonizes the human body, is derived from mother’s 
vaginal microbiota or skin during the process of birth. This clearly indicates the 
absolute importance of a balanced vaginal microbiota since it contributes to the normal 
delivery and, later on governs the metabolic fate of an individual. This in turn opens up 
a wide scope for developing new strategies to improve mother’s vaginal microbiota 
during the pregnancy period in order to improve child health and prevent premature 
birth. One of the strategies could be the use of probiotic vaginal Lactobacillus strains 
during the pregnancy. The probiotic lactobacilli could be provided in formulations like 
yoghurt, drink or a vaginal capsule containing freeze-dried lactobacilli. 
 
 
Addressing BV and VVC in Scandinavia by modifying clinical interventions and use of 
lactobacilli, we were able to improve cure rates. A long-term vaginal colonization by 
administered lactobacilli is of primary importance if we want to target African 
population where the prevalence of both BV and HIV-1 is the highest. Till date no 
Lactobacillus colonization study has been performed in South Africa and this is what 
we aim for taking a step forward in this direction. EcoVag
® 
lactobacilli will be assessed 
for colonization in South African women which would in turn have an impact on future 
studies. Having recently obtained the genome sequence of EcoVag
® 
lactobacilli, it will 
also be possible to perform quantitative analysis by real-time PCR and to follow the 
colonization of these strains over the menstruation cycle. With the emerging high 
throughput sequencing techniques, the vaginal microbiome and the shift in microbial 
populations could be studied both in women with normal microbiota and with BV 
before and after administration of EcoVag
®
. The possible gene interactions or the 
resulting pre and/or probiotic effects could also be studied using the gene microarray 
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technology benefiting the field of vaginal probiotics. If the EcoVag
® 
strains appear not 
to colonise women in South Africa, Lactobacillus strains isolated from South African 
women could be further characterized and tested for colonization. 
 
 
To overcome the hurdles related to the use of current microbicide formulations against 
HIV-1 infection, a novel strategy would be to genetically modify the probiotic 
lactobacilli to deliver therapeutic molecules on the mucosal surface in the vagina. The 
best colonizing Lactobacillus strains from our study in South Africa could be 
engineered for production of VHH and, these recombinant designer probiotic 
lactobacilli could colonize the vagina and produce VHH in situ. To stabilize the 
expression of VHH, the VHH encoding gene will be inserted in the Lactobacillus 
genome and the gene encoding thymidine will be knocked down in order to ensure that 
the genetically modified lactobacilli will not survive outside the human body. However, 
before performing a clinical trial with the genetically modified lactobacilli, the concept 
will have to be tested in a non-human primate model, in order to ensure that the 
modified lactobacilli are protective against mucosal SHIV challenge. An added benefit 
with the VHH conferred by its small size is that, they could be expressed as homo/hetro 
dimers increasing the avidity with similar specificity. This would also overcome the 
problem of relative lower expression of the recombinant VHH in lactobacilli. 
 
 
The  modified  lactobacilli  could  be  freeze  dried  and  incorporated  in  capsules  or 
tampons, allowing the stockpiling of microbicide without any need of strict storage 
conditions. Once administered, the lactobacilli would colonize the vagina and persist 
while producing the microbicide in situ. This would bypass the need of repeated and 
frequent administration. To conclude, Lactobacillus based strategies for the delivery of 
microbicides against HIV-1 or other sexually transmitted pathogen, would function as a 
bi-headed arrow, where one arm would target for an improvement of the host heath and 
another arm to prevent pathogen from causing infection. The strategy thus offers a 
discrete, affordable, easy to use and coitally independent HIV prevention, which can be 
applied against various pathogens and could be reciprocated in a bigger population with 
no known side effects. 
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8    POPULAR SCIENCE SUMMARY 
The female body is a complex and delicate system that plays a major role in flourishing 
the human society but, this also exposes them to various health complications. 
Disturbance of the balance of beneficial and non-beneficial bacteria residing in the 
vagina is one such example where, our own body, physical/sexual activity and 
environmental factors influence this balance. Lactobacilli in the vagina are such 
beneficial bacteria, which maintain the vaginal environment by producing acid and 
compounds active against other microbes. The disturbed balance of vaginal bacteria 
causes health issues like bacterial vaginosis (BV) and yeast infection (vulvovaginal 
candidiasis (VVC)), which in turn amplifies the risk of getting infected by other 
pathogens including HIV-1. Theoretically, in such a condition one has to deal with two 
different health complications at the same time and therefore, an approach towards 
these issues would be to bring back the dominance of beneficial bacteria in vagina and 
to equip these bacteria to produce anti-microbials that will kill pathogens. Thus, 
the basis of the thesis work can be very simply read through the conversation below: 
 
 
 
 
Patient: Hello Dr., I have vaginal discharge and foul smell and itching 
too. Is that a sign of an infection? 
 
 
 
 
 
 
Dr.: Yes, these are the signs of a vaginal infection. It happens when 
you lose the beneficial bacteria and other non-beneficial ones 
overgrow. But don’t worry, I will give you some probiotic bacteria 
that will improve your symptoms and will also protect you from other infections. 
 
 
 
 
 
But Dr., how does this work? 
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Dr.: Hmmm, well, imagine the society we live in. We have all kinds of 
people living together, but there are some who can cause trouble to others. 
Therefore, we have police, the ones who are chosen from our own society 
because they are strong, brave and show characteristics of a soldier. They are selected 
and trained to combat bad elements in our society. They learn tactics for fighting and to 
use a weapon when needed for protecting the society. In this way, they maintain law 
and order, and if we are attacked by some highly trained enemies then, our police uses 
equally or even better combat skills to bring them down and save the society from 
destruction. 
So, who’s who Doctor??? 
 
 
Dr.: Our body is like a society, where all different good and bad bacteria 
live together. When the bad bacteria start to grow more than the good 
ones, they cause trouble to our body. Therefore, we need the good bacteria, 
which can reside in our body and fight with the bad ones. Thus, the good bacteria are 
chosen from our own body after a lot of research and are designed to produce 
compounds that will stop a pathogen from causing infection. 
 
 
 
 
Wow, that sounds exciting and safe. Thank you! 
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